The coincidence of autoantibodies against the acetylcholine receptor (AChR) and muscle striational antigens (SA) is a characteristic finding in thymoma-associated myasthenia gravis (MG), but their origins are still unresolved. Some common muscle antigens that were shown to be targets of anti-SA autoantibodies in thymoma-associated MG have also been detected in normal or neoplastic th)fmic epithelial cells, suggesting that the release of (eventually altered) antigens from the thymic tumors Could elicit SA autoimmunity. In contrast to this model, we report here that titin, which is a recently reported target of SA autoimmunity, is not expressed in thymomas. In addition, we show that skeletal muscle type-II fibers exhibit a striational immunoreactivity with monoclonal antibody mAb155, which was previously identified to label a very immunogenic cytoplasmic epitope of the AChR and neoplastic epithelial cells of MGassociated thymomas. We conclude from these findings that titin autoimmunity in thymoma-associated MG is either due to a molecular mimicry mechanism involving tumor antigens (other than titin) or is a secondary phenomenon following release of titin from muscle. Based on the common immunoreactivity of the AChR, a striational antigen and thymoma, we suggest as the pathogenetic mechanism of thymoma-associated MGa "circulus vitiosus" in which SA autoimmunity could help maintain the AChR autoimmunity that is primarily elicited by the thymomas.
INTRODUCTION
Myasthenia gravis (MG) is characterized by an abnormal fatiguability of muscle produced in most patients by autoantibodies against the nicotinic acetylcholine receptor (AChR) . These autoantibodies are thought to impair neuromuscular transmission by reducing the number of muscle endplate AChR or blocking their function (Drachman, et al., 1980; Burges et al., 1990) In addition to anti-AChR autoimmunity, 70% of MG patients exhibit thymitis with or without *Corresponding author: Present address: Pathologisches Institut der Universit/it, Josef Schneider Str. 2, 8700 W(irzburg, Germany. lymphofollicular hyperplasia (M(iller-Hermelink et al., 1986; Kirchner et al., 1986 ) and 10% have a thymoma (Kirchner and MiJller-Hermelink, 1989) . As an important diagnostic feature, only the latter group of MG patients almost invariably has high titers of heterogeneous autoantibodies against striational muscle antigens (SA) in addition to anti-AChR autoantibodies (Peers et al., 1977; Aarli et al., 1990; Connor et al., 1990; Ohta et al., 1990) . In thymoma patients without MG anti-SA autoantibodies occur in only 24% (Williams and Lennon, 1987) .
How SA autoimmunity is elicited in thymomas is not known. However, the finding that myosin and some less well-defined muscle proteins are anti-SA-autoantibody targets that also occur in normal or neoplastic thymic epithelial cells (Gilhus et al., 1984; Williams and Lennon, 1987; Dardenne et al., 1987) Recently, titin was identified as a major target of anti-SA autoantibodies in MG (Aarli et al., 1990 (Fig. 2c) .
Because of the high incidence of antititin autoantibodies typical of MG/thymoma patients (Aarli et al., 1990) , we looked for an aberrant expression of titin in thymoma because the denovo expression of other proteins has previously been reported as a typical feature of neoplastic thymic epithelium Marx et al., 1990 Marx et al., , 1991 . However, with respect to the FIGURE 1. Immunoreactivity of a few round or spindle-shaped cells inside the human thymic medulla with antititin monoclonal antibodies T4 (a), T12 (b), and T32 (c). Morphology and localization are typical of thymic myoid cells (cf. Fig. 2 (a) . No reactivity of muscle with anti-AChR mAb195 directed against the AChR "main immunogenic region" (Tzartos et al., 1983) (b) . In contrast to the striational immunoreactivity of mAb155, the immunoreactivity with antititin mAb T12 is encountered in 100% of muscle fibers (c), demonstrating the nonidentity of titin and the AChR-epitope-bearing striational antigen in human quadriceps muscle (all sections #$361). Frozen sections, immunoperoxidase (x400). have to prove whether the striational antigen immunolabeled by mAb155 (Fig. 4a) is identical to the thymoma proteins bearing the AChR epitope detected by mAb 155 Quadriceps muscle +c aImmunoreactivity with anti-AChR mAb155 (Tzartos et al., 1986) .
bImmunoreactivity of mAb155 with thymic myoid cells and medullary epithelial cells (Dubowitz, 1985) . Tzartos et al., 1986 Tzartos et al., 1988 aMIR=main immunogenic region (Tzartos et al., 1988 
